Avobis Bio to Present at American College of Gastroenterology’s 2025 Annual Scientific Meeting

Avobis Bio is pleased to announce that the primary analysis results of the phase II prospective, randomized STOMP-II clinical trial will be presented at ACG’s 2025 Annual Scientific Meeting.  The STOMP-II trial is assessing AVB-114, Avobis Bio’s lead implantable cell therapy candidate, against the standard of care for the treatment of Crohn’s Disease perianal fistulas.   More information on the study (NCT04847739) is available at www.clinicaltrials.gov.

Dr. David Schwartz, a STOMP-II investigator, Professor of Medicine in the Division of Gastroenterology, Hepatology and Nutrition, and Department of Medicine, and Director of the Inflammatory Bowel Disease Center at Vanderbilt University Medical Center, will present the results at Plenary Session 4B:IBD on Wednesday October 29, 2025.  Please join us in Phoenix, AZ to hear the results of the STOMP-II clinical trial.

Tiffany J. Brown, PhD

Chief Executive Officer

Tiffany leads Avobis Bio as Chief Executive Officer, Chief Compliance Officer and Board Member. She has been passionate about regenerative medicine for 25 years and focused her career on ensuring patients have access to therapies to transform their lives. In her early career, Tiffany developed new products from clinical concept through technology development, global regulatory approvals and commercial sales. She went on to lead a multi-million dollar global portfolio of therapeutics for general surgical, bariatric and colorectal conditions with assets from pre-clinical stage to market leaders. Tiffany was instrumental in the formation of Avobis Bio, bringing together capabilities of Gore and Mayo Clinic, establishing the team and accelerating operational execution. She holds a PhD in Biomedical Engineering from Georgia Tech and Emory University. Tiffany enjoys immersion in global cultures, opportunities to travel and staying active with her husband and children.